ARDX vs UNCY
ARDX: A commercial-stage biotech company leveraging its proprietary NHE3 inhibitor platform to treat gastrointestinal and cardiorenal conditions. UNCY: A clinical-stage biotechnology company developing novel treatments for patients with chronic and acute kidney disease, including a next-generation phosphate binder for hyperphosphatemia.
Side-by-side fundamentals
| Metric | ARDX | UNCY | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $3.27 | $4.07 | |
| Market cap | $815M | $113M | |
| Net margin | -15.1% | -4525.0% | ARDX higher |
| Operating margin | -10.1% | -3077.6% | ARDX higher |
| ROE FY2025, SEC XBRL | -36.9% | -87.9% | ARDX higher |
| ROA FY2025, SEC XBRL | -12.3% | -54.0% | ARDX higher |
| Debt / equity as of 2026-09-03 | 1.69 | 0.00 | UNCY lower |
| Revenue growth (YoY) as of 2026-09-03 | +16.8% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +98.4% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-09-03 | 0.71 | 0.93 | |
| 1-year return as of 2026-10-08 close | -35.4% | -14.7% | UNCY higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.